ClinicalTrials.gg
RecruitingNCT07280013Updated Oct 30, 2026

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

A Phase 1 interventional study of Cemsidomide and Elranatamab in Multiple Myeloma (MM), sponsored by C4 Therapeutics, Inc.. Recruiting at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by C4 Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 30, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Planned enrollment
637th of 1,901
60 · median 36
Started
2026
with 75 others
Phase 1
559 of 2,168
64 open now
Primary completion
2028-12
later than 376 of 499 live
Registered
2,114th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 637th largest by planned enrollment of the 1,901 interventional ones that give a count, is one of 76 that started in 2026, is one of 559 in phase 1, reaches primary completion later than 376 of the 499 other live ones, and was the 2,114th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.

The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity.

Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

03

Conditions studied

  • Multiple Myeloma (MM)

Keywords

  • multiple myeloma, cemsidomide, CFT7455, elranatamab, PF-06863135, relapsed, refractory, RRMM, BCMA, bispecific antibody, BiTE, TCE, ELREXFIO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma as defined by IMWG criteria
  • based on IMWG criteria
  • Received 2-4 (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader)
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia, Smoldering multiple myeloma, POEMS Syndrome, systemic light chain amyloidosis, MDS
  • Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
  • Participants with any active, uncontrolled bacterial, fungal, or viral infection
  • Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy
  • Administration with an product within 30 days preceding the first dose of study intervention
  • Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Non-randomized cemsidomide (tablet) plus elranatamab (subcutaneous injection)

    Drug: Cemsidomide · Biological: Elranatamab

Interventions

  • IKZF1/3 degrader

  • BiologicalElranatamab

    • BCMA-CD3 bispecific antibody

    Also known as: o PF-06863135 o ELREXFIO

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of cemsidomide in combination with elranatamab

    Dose limiting toxicity rate

    Time frame: Cycle 1 approximately 28 days

  2. Safety and tolerability of cemsidomide in combination with elranatamab

    Frequency and severity of AEs

    Time frame: Baseline through 30 days after discontinuation of study treatment

Secondary outcomes

  1. Assess antimyeloma activity

    Objective Response Rate (ORR) per IMWG criteria

    Time frame: Approximately 2 years

  2. Evaluate the PK of cemsidomide and elranatamab

    Pre and post dose concentrations of cemsidomide

    Time frame: Approximately 4 months

  3. Evaluate the PK of cemsidomide and elranatamab

    Pre dose concentrations of elranatamab

    Time frame: Approximately 2 years

  4. Assess the immunogenicity of elranatamab

    Percent of participants with positive anti-drug antibodies to elranatamab

    Time frame: Approximately 2 years

07

Study locations

12 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 34 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Feb 6, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • UC Davis Comprehensive Cancer Center · Sacramento, United StatesNot yet recruiting→Recruiting
  • UCLA Health, Jonsson Comprehensive Cancer Center · Santa Monica, United StatesNot yet recruiting→Recruiting
  • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesNot yet recruiting→Recruiting
  • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
Show 1 removed
  • University of Florida · Gainesville, United States
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site removed. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • UC Davis Comprehensive Cancer Center · Sacramento, United StatesNot yet recruiting→Recruiting
    • UCLA Health, Jonsson Comprehensive Cancer Center · Santa Monica, United StatesNot yet recruiting→Recruiting
    • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesNot yet recruiting→Recruiting
    • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
    Show 1 removed
    • University of Florida · Gainesville, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07280013
Lead sponsor
C4 Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Feb 6, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Study Medical Officer
Contact
clinicaltrials@c4therapeutics.com
(617) 231-0700

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemsidomide

Start the discussion